Jodi Gilman, PhD
Director for Neuroscience Center for Addiction Medicine. Assistant Professor, Harvard Medical School
Contact: firstname.lastname@example.org (617) 643-7293
Dr. Gilman is a highly productive neuroscientist focused on the neurobiological determinants and consequences of drug use. She conducted her post-doctoral fellowship with Dr. Evins, is now an Assistant Professor at HMS, has been proposed for promotion to Associate Professor, and serves as Director for Neuroscience at the MGH CAM. She completed NIDA K01 DA034093 Neurobehavioral Characterization of Social Influence in Drug Addiction and Harvard Zinberg Award in Clinical Addiction Research Decision-Making in the Context of Social Influence in Young Adult Marijuana Users with Dr. Evins as primary mentor. She is now supported by R01DA042043 Medical Marijuana, Neurocognition and Subsequent Substance Use and has submitted R01DA042787, The Effect of Marijuana Abstinence on Mood and Cognition in Regular Marijuana Users with Major Depressive Disorder. Dr. Gilman has successfully mentored pre-doctoral students who are now pursuing PhDs in neuroscience in excellent laboratories around the country and now is mentoring two post-doctoral and two pre-doctoral fellows.
Neurobehavioral characterization of social influence in drug addiction
NIDA 4K01DA034093 2013-18
To understand the role of social decision-making in drug use by conducting a neuroimaging study in marijuana-using young adults and matched controls which will allow us to (1) determine whether there is a difference between the groups in susceptibility to social influence, and (2) evaluate the relationship between social influence behavior and neural activation in brain circuits underlying social learning
Medical marijuana, neurocognition, and subsequent substance use
NIDA R01DA042043 2016-21
This study will use a randomized controlled trial design to test whether medical marijuana patients experience unintended negative consequences from medical marijuana use such as progression to addiction, neurocognitive impairments, and brain-based changes. The resulting data will inform clinicians, scientists, and policy-makers about unforeseen effects and potential outcomes of medical marijuana policies.